Amir A Jazaeri
Overview
Explore the profile of Amir A Jazaeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
How J, Jazaeri A
Med
. 2025 Jan;
6(1):100558.
PMID: 39798550
Although there is anti-tumor efficacy of dual CTLA-4/PD-1 blockade in advanced/recurrent cervical cancer, it is unclear whether combination with chemotherapy is synergistic. In COMPASSION-16, Wu et al. demonstrated improved survival...
2.
How J, Jazaeri A, Westin S, Lawson B, Klopp A, Soliman P, et al.
Nat Rev Clin Oncol
. 2024 Aug;
21(11):781-800.
PMID: 39198622
Endometrial cancer (EC) is the most common gynaecological cancer among women in high-income countries, with both incidence and mortality continuing to increase. The complexity of the management of patients with...
3.
Jiang J, Liu Y, Qin J, Chen J, Wu J, Pizzi M, et al.
Nat Commun
. 2024 Aug;
15(1):7312.
PMID: 39181865
Recent advances in spatial transcriptomics (ST) techniques provide valuable insights into cellular interactions within the tumor microenvironment (TME). However, most analytical tools lack consideration of histological features and rely on...
4.
How J, Dang M, Lee S, Fellman B, Westin S, Sood A, et al.
Med
. 2024 Aug;
6(1):100494.
PMID: 39151421
Background: The efficacy and feasibility of pembrolizumab combined with chemotherapy in frontline management of advanced high-grade epithelial ovarian cancer (EOC) is unknown. Additionally, modification of the tumor microenvironment following neoadjuvant...
5.
Wilke R, Iniesta M, Fellman B, Jazaeri A, Meyer L, Fleming N, et al.
Gynecol Oncol
. 2024 Jun;
188:120-124.
PMID: 38945019
Objectives: Malignant large bowel obstruction (LBO) is a frequent complication affecting women with gynecologic cancers and is an indication for emergent surgery. However, the life expectancy and subsequent medical care...
6.
How J, Jazaeri A
Med
. 2024 Jun;
5(6):487-489.
PMID: 38878765
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC...
7.
Knisely A, Hinchcliff E, Gardiner E, Rangwala R, Lito K, Fellman B, et al.
iScience
. 2024 May;
27(5):109801.
PMID: 38726365
Combining an immune checkpoint inhibitor with batiraxcept (AVB-S6-500), an AXL inhibitor that acts via selective binding to growth arrest-specific protein 6 (GAS6), may improve anti-tumor immunity in platinum-resistant ovarian cancer...
8.
Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, et al.
Clin Cancer Res
. 2024 Apr;
30(14):2986-2995.
PMID: 38687597
Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular...
9.
Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, et al.
Med
. 2024 Mar;
5(4):311-320.e3.
PMID: 38471508
Background: Intravenous immune checkpoint blockade (ICB) has shown poor response rates in recurrent gynecologic malignancies. Intraperitoneal (i.p.) ICB may result in enhanced T cell activation and anti-tumor immunity. Methods: In...
10.
Amaria R, Knisely A, Vining D, Kopetz S, Overman M, Javle M, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38309721
Background: Tumor-infiltrating lymphocyte (TIL) therapy has shown efficacy in metastatic melanoma, non-small cell lung cancer, and other solid tumors. Our preclinical work demonstrated more robust CD8 predominant TIL production when...